Robert Burns

Q: How accurate are Robert Burns's stock ratings?

About 41% of Robert's ratings were profitable over a one-year hold, with an average return of -4.8% per rating, measured by 13Foresight from historical prices.

Q: How is Robert ranked?

Robert Burns is ranked #1200 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

H.C. Wainwright

Wall Street Analyst

★★★☆☆

#1200

on 13Foresight · ranked by our own returns

41%

Success Rate

-4.8%

Average Return

45 of 110 calls profitable · +21.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 41% of Robert Burns's ratings turned a profit when each position was held for 1 year — averaging -4.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

218 Buy 8 Hold 1 Sell

Robert's Stock Coverage 52 ratings · 2026-09-28

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
TLX Telix Pharmaceuticals Limited Unsponsored ADR	Sep 25, 2026	BUY	Strong Buy +74.6% avg upside 2 analysts	$20.00 74.64% Upside	·	·
CGEM Cullinan Management	Sep 25, 2026	BUY	Strong Buy +138.4% avg upside 16 analysts	$35.00 136.34% Upside	+0.0%	·
BLSM BlossomHill Therapeutics, Inc.	Sep 24, 2026	BUY	Strong Buy +79.2% avg upside 5 analysts	$35.00 77.24% Upside	·	·
ACET Adicet Bio	Sep 21, 2026	BUY	Strong Buy +180.9% avg upside 14 analysts	$27.00 199.39% Upside	+1.0%	·
COGT Cogent Biosciences	Sep 16, 2026	BUY	Strong Buy +19.7% avg upside 26 analysts	$55.00 70.16% Upside	-3.0%	·
CRDF Cardiff Oncology	Sep 15, 2026	BUY	Buy +756.7% avg upside 18 analysts	$9.00 625.90% Upside	-7.5%	·
INBX Inhibrx Biosciences Inc	Sep 09, 2026	BUY	Strong Buy +167.7% avg upside 6 analysts	$245.00 145.88% Upside	-11.7%	·
PMVP PMV Pharmaceuticals	Sep 08, 2026	BUY	Strong Buy +937.8% avg upside 13 analysts	$5.00 275.87% Upside	-0.8%	·
RVMD Revolution Medicines	Aug 27, 2026	BUY	Strong Buy -1.4% avg upside 33 analysts	$280.00 36.55% Upside	-7.3%	·
ZYME Zymeworks	Aug 26, 2026	BUY	Strong Buy +26.0% avg upside 26 analysts	$55.00 107.38% Upside	-9.5%	·
RLAY Relay Therapeutics	Aug 21, 2026	BUY	Strong Buy +27.4% avg upside 21 analysts	$29.00 66.09% Upside	-10.1%	·
ELTX Elicio Therapeutics	Aug 21, 2026	BUY	Buy +665.9% avg upside 11 analysts	$23.00 1150.08% Upside	-37.2%	·
HURA TuHURA Biosciences	Aug 20, 2026	BUY	Strong Buy +338.1% avg upside 8 analysts	$10.00 376.18% Upside	-5.4%	·
TNGX Tango Therapeutics	Aug 18, 2026	BUY	Strong Buy +57.4% avg upside 15 analysts	$68.00 172.86% Upside	-2.8%	·
AVBP ArriVent BioPharma, Inc.	Aug 17, 2026	BUY	Strong Buy +53.0% avg upside 15 analysts	$47.00 65.14% Upside	-1.9%	·
IMMX Immix Biopharma	Aug 10, 2026	BUY	Strong Buy +81.2% avg upside 9 analysts	$25.00 127.91% Upside	+8.3%	·
ORIC Oric Pharmaceuticals	Aug 10, 2026	BUY	Strong Buy +82.3% avg upside 20 analysts	$27.00 105.18% Upside	-3.2%	·
NUVB Nuvation Bio	Aug 07, 2026	BUY	Strong Buy +132.3% avg upside 17 analysts	$21.00 265.82% Upside	-13.0%	·
BDTX Black Diamond Therapeutics	Aug 06, 2026	BUY	Strong Buy +660.6% avg upside 12 analysts	$11.00 485.08% Upside	-2.1%	·
KPTI Karyopharm Therapeutics	Jul 31, 2026	HOLD	Strong Buy +1038.7% avg upside 18 analysts	$3.00 85.16% Upside	-8.8%	·
PRLD Prelude Therapeutics	Jul 29, 2026	BUY	Buy +180.2% avg upside 7 analysts	$8.00 106.46% Upside	-15.3%	·
OKUR OnKure Therapeutics	Jul 20, 2026	BUY	Buy +672.3% avg upside 13 analysts	$21.00 624.15% Upside	-29.6%	·
NRIX Nurix Therapeutics	Jul 10, 2026	BUY	Strong Buy +39.0% avg upside 28 analysts	$34.00 47.67% Upside	-0.2%	·
ELVN Enliven Therapeutics	Jul 09, 2026	BUY	Strong Buy +33.8% avg upside 16 analysts	$65.00 45.29% Upside	-14.2%	·
FATE Fate Therapeutics	Jul 09, 2026	BUY	Buy +415.8% avg upside 31 analysts	$7.00 197.97% Upside	-24.4%	·
MOLN Molecular Partners	Jul 06, 2026	BUY	Strong Buy +132.5% avg upside 7 analysts	$13.00 202.30% Upside	+5.2%	·
EXEL Exelixis	Jul 02, 2026	BUY	Buy -27.0% avg upside 34 analysts	$56.00 3.62% Downside	+4.1%	·
CRBU Caribou Biosciences	Jun 16, 2026	BUY	Strong Buy +794.4% avg upside 12 analysts	$11.00 787.19% Upside	-26.6%	·
ADCT ADC Therapeutics	Jun 08, 2026	HOLD	Buy +306.8% avg upside 12 analysts	—	+34.0%	·
RADX Radiopharm Theranostics Limited Sponsored ADR	Jun 04, 2026	BUY	Strong Buy +1010.7% avg upside 6 analysts	$16.00 869.67% Upside	-65.2%	·
AKTS Aktis Oncology, Inc.	Jun 03, 2026	BUY	Strong Buy +70.0% avg upside 12 analysts	$35.00 80.23% Upside	+0.3%	·
CATX Perspective Therapeutics	Jun 01, 2026	BUY	Strong Buy +338.2% avg upside 24 analysts	$13.00 415.88% Upside	-31.1%	·
BCAX Bicara Therapeutics Inc.	Jun 01, 2026	BUY	Strong Buy +71.1% avg upside 16 analysts	$42.00 118.69% Upside	-6.8%	·
BOLT Bolt Biotherapeutics	May 28, 2026	BUY	Buy +626.3% avg upside 7 analysts	$7.00 95.59% Upside	-32.5%	·
MGNX MacroGenics	May 07, 2026	HOLD	Buy +374.1% avg upside 25 analysts	—	+40.1%	·
BBOT BridgeBio Oncology Therapeutics	May 01, 2026	BUY	Strong Buy +454.1% avg upside 11 analysts	$29.00 634.26% Upside	-52.9%	·
BNTX BioNTech SE	Apr 27, 2026	BUY	Strong Buy +36.4% avg upside 26 analysts	$130.00 31.86% Upside	-3.5%	·
WHWK Whitehawk Therapeutics	Apr 21, 2026	HOLD	Strong Buy +233.5% avg upside 14 analysts	—	-10.9%	·
ALLO Allogene Therapeutics	Apr 16, 2026	BUY	Strong Buy +825.1% avg upside 28 analysts	$11.00 566.62% Upside	-31.4%	·
REPL Replimune Group	Apr 13, 2026	SELL	Strong Buy +86.8% avg upside 14 analysts	—	-657.1%	·
AUTL Autolus Therapeutics	Feb 13, 2026	BUY	Strong Buy +475.2% avg upside 16 analysts	$8.00 331.31% Upside	+32.5%	·
ATRA Atara Biotherapeutics	Aug 19, 2025	HOLD	Buy +105.4% avg upside 18 analysts	—	-16.4%	·
APLM Apollomics	Sep 03, 2024	HOLD	Buy -29.5% avg upside 3 analysts	—	-62.9%	·
EFTR eFFECTOR Therapeutics	Jul 16, 2024	HOLD	Buy +66249900.1% avg upside 5 analysts	—	·	·
GTBP GT Biopharma	May 24, 2024	HOLD	Buy +52.4% avg upside 3 analysts	—	-21.5%	·
CLDI Calidi Biotherapeutics	Mar 21, 2024	BUY	Strong Buy +860.8% avg upside 3 analysts	$20.00 1669.88% Upside	·	·
ALP Alpha Compute	Jan 08, 2024	HOLD	Strong Buy +202.4% avg upside 7 analysts	—	·	·
NGNE Neurogene	Mar 21, 2023	HOLD	Strong Buy +72.2% avg upside 23 analysts	—	+269.0%	·
IMA ImageneBio	Mar 17, 2023	BUY	Strong Buy +279.2% avg upside 13 analysts	$22.00 366.06% Upside	-61.8%	·
CTMX CytomX Therapeutics	May 10, 2022	BUY	Strong Buy +299.7% avg upside 21 analysts	$11.00 307.32% Upside	+2.2%	·
SE:ONCO Oncopeptides AB	Oct 22, 2021	SELL	Sell 2 analysts	—	-205.7%	·
NCNA Nucana	Mar 05, 2021	BUY	Buy +884.4% avg upside 9 analysts	$10.00 681.23% Upside	·	·

🔒 47 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Robert Burns — Frequently Asked Questions

How accurate are Robert Burns's stock ratings?

Based on the calls 13Foresight could measure, about 41% of Robert's ratings were profitable over a one-year hold, with an average return of -4.8% per rating, or +21.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Robert ranked on 13Foresight?

Robert Burns is currently ranked #1200 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Robert cover?

Robert most recently has ratings on TLX, CGEM, BLSM, ACET, COGT, CRDF, INBX, PMVP, RVMD, ZYME, RLAY, ELTX and 40 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Robert Burns

Rating Distribution

Welcome to 13Foresight!